Industry Symposium by Bracco
Gadopiclenol (Vueway) is a highly stable, macrocyclic, gadolinium-based contrast agent (GBCA) with the highest r1 relaxivity of all GBCAs that are currently available or in development. The benefits of high relaxivity are that it can be administered at a lower dose without loss of diagnostic efficacy and that less gadolinium enters the environment. Lower Gd doses may be particularly beneficial in young, pediatric patients and in patients that require long-term regular MRI screening or follow-up. This symposium includes presentations by Prof. Andrea Rossi on the overall safety and benefits of low dose, high relaxivity Vueway for pediatric imaging and Prof. Daniela Bernardi on the advantages of Vueway for imaging of the breast. Finally, even with the highest r1 relaxivity available, some lesions may remain poorly visible at the approved GBCA dose. The symposium concludes with a presentation by Prof. Josef Vymazal on the improved lesion conspicuity provided by AI (AiMIFY) when used in conjunction with Vueway at its approved dose.